BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23952243)

  • 1. Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
    Walker AR; Klisovic RB; Garzon R; Schaaf LJ; Humphries K; Devine SM; Byrd JC; Grever MR; Marcucci G; Blum W
    Leuk Lymphoma; 2014 Jun; 55(6):1304-8. PubMed ID: 23952243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
    Blum W; Schwind S; Tarighat SS; Geyer S; Eisfeld AK; Whitman S; Walker A; Klisovic R; Byrd JC; Santhanam R; Wang H; Curfman JP; Devine SM; Jacob S; Garr C; Kefauver C; Perrotti D; Chan KK; Bloomfield CD; Caligiuri MA; Grever MR; Garzon R; Marcucci G
    Blood; 2012 Jun; 119(25):6025-31. PubMed ID: 22566605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
    Horton TM; Perentesis JP; Gamis AS; Alonzo TA; Gerbing RB; Ballard J; Adlard K; Howard DS; Smith FO; Jenkins G; Kelder A; Schuurhuis GJ; Moscow JA
    Pediatr Blood Cancer; 2014 Oct; 61(10):1754-60. PubMed ID: 24976003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.
    Howard DS; Liesveld J; Phillips GL; Hayslip J; Weiss H; Jordan CT; Guzman ML
    Leuk Res; 2013 Nov; 37(11):1502-8. PubMed ID: 24075534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
    Attar EC; Johnson JL; Amrein PC; Lozanski G; Wadleigh M; DeAngelo DJ; Kolitz JE; Powell BL; Voorhees P; Wang ES; Blum W; Stone RM; Marcucci G; Bloomfield CD; Moser B; Larson RA
    J Clin Oncol; 2013 Mar; 31(7):923-9. PubMed ID: 23129738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
    Attar EC; De Angelo DJ; Supko JG; D'Amato F; Zahrieh D; Sirulnik A; Wadleigh M; Ballen KK; McAfee S; Miller KB; Levine J; Galinsky I; Trehu EG; Schenkein D; Neuberg D; Stone RM; Amrein PC
    Clin Cancer Res; 2008 Mar; 14(5):1446-54. PubMed ID: 18316568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
    Walter RB; Medeiros BC; Gardner KM; Orlowski KF; Gallegos L; Scott BL; Hendrie PC; Estey EH
    Haematologica; 2014 Jan; 99(1):54-9. PubMed ID: 24142996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.
    Stevens B; Winters A; Gutman JA; Fullerton A; Hemenway G; Schatz D; Miltgen N; Wei Q; Abbasi T; Vali S; Singh NK; Drusbosky L; Cogle CR; Hammes A; Abbott D; Jordan CT; Smith C; Pollyea DA
    Leuk Res; 2019 Jun; 81():43-49. PubMed ID: 31009835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.
    Garcia-Manero G; Abaza Y; Takahashi K; Medeiros BC; Arellano M; Khaled SK; Patnaik M; Odenike O; Sayar H; Tummala M; Patel P; Maness-Harris L; Stuart R; Traer E; Karamlou K; Yacoub A; Ghalie R; Giorgino R; Atallah E
    Blood Adv; 2019 Feb; 3(4):508-518. PubMed ID: 30760466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
    Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
    [No Abstract]   [Full Text] [Related]  

  • 12. A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia.
    Medeiros BC; Tanaka TN; Balaian L; Bashey A; Guzdar A; Li H; Messer K; Ball ED
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):346-352.e5. PubMed ID: 29572158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
    Wei A; Tan P; Perruzza S; Govindaraj C; Fleming S; McManus J; Avery S; Patil S; Stevenson W; Plebanski M; Spencer A
    Br J Haematol; 2015 Apr; 169(2):199-210. PubMed ID: 25643589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
    Attar EC; Amrein PC; Fraser JW; Fathi AT; McAfee S; Wadleigh M; Deangelo DJ; Steensma DP; Stone RM; Foster J; Neuberg D; Ballen KK
    Leuk Res; 2013 Sep; 37(9):1016-20. PubMed ID: 23773898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
    Daver N; Garcia-Manero G; Basu S; Boddu PC; Alfayez M; Cortes JE; Konopleva M; Ravandi-Kashani F; Jabbour E; Kadia T; Nogueras-Gonzalez GM; Ning J; Pemmaraju N; DiNardo CD; Andreeff M; Pierce SA; Gordon T; Kornblau SM; Flores W; Alhamal Z; Bueso-Ramos C; Jorgensen JL; Patel KP; Blando J; Allison JP; Sharma P; Kantarjian H
    Cancer Discov; 2019 Mar; 9(3):370-383. PubMed ID: 30409776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
    DiNardo CD; Pratz K; Pullarkat V; Jonas BA; Arellano M; Becker PS; Frankfurt O; Konopleva M; Wei AH; Kantarjian HM; Xu T; Hong WJ; Chyla B; Potluri J; Pollyea DA; Letai A
    Blood; 2019 Jan; 133(1):7-17. PubMed ID: 30361262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
    Walker AR; Wang H; Walsh K; Bhatnagar B; Vasu S; Garzon R; Canning R; Geyer S; Wu YZ; Devine SM; Klisovic R; Blum W; Marcucci G
    Leuk Lymphoma; 2016 Sep; 57(9):2100-8. PubMed ID: 26784138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
    Halpern AB; Othus M; Huebner EM; Buckley SA; Pogosova-Agadjanyan EL; Orlowski KF; Scott BL; Becker PS; Hendrie PC; Chen TL; Percival MM; Estey EH; Stirewalt DL; Walter RB
    Leukemia; 2017 Dec; 31(12):2560-2567. PubMed ID: 28555084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
    Walker AR; Klisovic R; Johnston JS; Jiang Y; Geyer S; Kefauver C; Binkley P; Byrd JC; Grever MR; Garzon R; Phelps MA; Marcucci G; Blum KA; Blum W
    Leuk Lymphoma; 2013 Sep; 54(9):1996-2002. PubMed ID: 23256542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
    Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
    Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.